BioCancell Therapeutics Inc. is a biotechnology company specializing in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search and destroy paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are highly expressed only in tumors. BioCancell Therapeutics Inc. holds granted and pending patents including the use of the H19 gene as a tumor marker, methods and compositions for inducing tumor-specific cytotoxicity, method for detection of micro-metastasis, H19 siRNA and methods and composition for inducing selective expression in tumor cells of the A subunit of the Diphtheria Toxin and the TNF alpha genes under the control of H19 promoter (H19 + TNF alpha).